Johnson & Johnson

Johnson & Johnson is recalling 200,000 bottles of Motrin Infants formula due to the risk that they contain tiny plastic particles.

Bottles of Tylenol sold in the U.S. will soon bear red warnings alerting users to the potentially fatal risks of taking too much of the popular pain reliever. The unusual step, disclosed by the company that makes Tylenol, comes amid a growing number of lawsuits and pressure from the federal government that could have widespread ramifications for a medicine taken by millions of people every day. Re

Johnson & Johnson is conducting a voluntary recall of millions of oral contraceptive packages in 43 countries outside the U.S., but says there's a "very low" risk that the flawed tablets could cause unplanned pregnancies.

Health care giant Johnson & Johnson says it's under investigation by federal prosecutors over the company's practices in marketing a line of hip replacements recalled two years ago because many failed and had to be replaced within five years.

Health care company Johnson & Johnson has been told to pay a Massachusetts teenager and her parents $63 million after she suffered a life-threatening drug reaction and lost most of her skin when she took a children's pain reliever nearly a decade ago.

Federal regulators say approval of the first generic version of cancer drug Doxil will help resolve a lingering shortage triggered by manufacturing deficiencies.

A panel of federal health experts has ruled that an experimental diabetes drug from Johnson & Johnson is safe and effective, though lingering safety questions must be tracked in long-term studies.

Federal drug reviewers think Johnson & Johnson's experimental diabetes drug might bring heart risks because it raised cholesterol levels in patient testing.

Pfizer Inc. and Johnson & Johnson say they are ending development of a once-promising drug designed to trea Alzheimer's disease after the treatment failed in two late-stage clinical trials.

A published report says Johnson & Johnson has agreed to pay as much as $2.2 billion to resolve an investigation into its marketing of the anti-psychotic drug Risperdal.